Clues To Gene Expression In Cystic Fibrosis Will Guide Research

Main Category: Cystic Fibrosis
Also Included In: Genetics
Article Date: 01 Apr 2007 - 3:00 PDT

email icon email to a friend   printer icon printer friendly   write icon opinions  

Current Article Ratings:

Patient / Public:5 stars

4.67 (3 votes)

Healthcare Prof:not yet rated


Genetics tests could help provide cystic fibrosis (CF) patients with targeted treatment in future, pilot study authors suggest. Results from a French clinical trial published today in BMC Medicine show how a small percentage of CF sufferers with a rare genetic stop mutation responded positively to gentamicin treatment.

Aleksander Edelman and Isabelle Sermet-Gaudelus of Faculté de Médicine Necker in Paris led collaborators from several French institutions studying how the antibiotic gentamicin affected CF patients with a stop mutation. The team used a dual reporter gene assay first in vitro and then in CF patients. The study found that a small subgroup of patients with the Y122X mutation, found mainly in inhabitants of Reunion island, responded to gentamicin treatment.

Cystic fibrosis is caused by mutations in the gene that encodes the Cystic Fibrosis Transmemrane Conductance Regulator (CFTR) protein. Over 1500 mutations have been described since this gene's discovery. Premature stop mutations, which includeY122X, are found in around 10% of CF patients. Gentamicin reversed stop codons in the Y122X gene, and helped restore the CFTR protein, improving patients' respiration.

Gentamicin itself may not be an ideal drug option, as it may cause serious side effects for some patients, including ear and kidney damage. The authors suggest that other drugs, such as amikacin or PTC124, with a comparable mode of action and fewer side effects, may have treatment potential. The in vitro method used to predict the trial's outcome could be a first step to developing treatments effective for patients with CF and other diseases where premature stop codons play a role.

###

Article:

In vitro prediction of stop-codon suppression by intravenous gentamicin in patients with cystic fibrosis. A pilot study. Isabelle Sermet-Gaudelus, Michel Renouil, Anne Fajac, Laure Bidou, Bastien Parbaille, Sébastien Pierrot, Nolwen Davy, Elise Bismuth, Philippe Reinert, Gérard Lenoir, Jean François Lesure , Jean Pierre Rousset, Aleksander Edelman. BMC Medicine (In press)

Contact: Martyn Thomas
BioMed Central

Article adapted by Medical News Today from original press release.
Visit our cystic fibrosis section for the latest news on this subject.
There are no references listed for this article.
Please use one of the following formats to cite this article in your essay, paper or report:

MLA
Martyn Thomas. "Clues To Gene Expression In Cystic Fibrosis Will Guide Research." Medical News Today. MediLexicon, Intl., 1 Apr. 2007. Web.
15 Feb. 2012. <http://www.medicalnewstoday.com/releases/66530.php>

APA
Martyn Thomas. (2007, April 1). "Clues To Gene Expression In Cystic Fibrosis Will Guide Research." Medical News Today. Retrieved from
http://www.medicalnewstoday.com/releases/66530.php.

Please note: If no author information is provided, the source is cited instead.


Cystic Fibrosis

Most Popular Articles



Follow Our Cystic Fibrosis News On Twitter

Follow Us On Twitter
Get the latest news for this category delivered straight to your Twitter account. Simply visit our Cystic Fibrosis Twitter account and select the 'follow' option.



View list of all 'What Is...' articles »